However, Dodick and collogues (61) found no increased risk of hypertension in patients with migraine who received erenumab in clinical trials and in the postmarketing setting and concluded that additional data are needed to fully characterize the extent to which hypertension is a risk associated with targeting CGRP pathway. The gene discussed is CALCA; the disease is hypertensive disorder.